MedPath

Muscle Oxygenation and Skin Pigmentation

Phase 4
Withdrawn
Conditions
Skin Pigmentation
Muscle Oxygenation
Interventions
Device: Measure of muscle oxygenation
Device: Skin pigmentation determination
Registration Number
NCT00747162
Lead Sponsor
Emory University
Brief Summary

The investigators plan to enroll 500 consecutive Subjects at a major trauma center for this study. For each patient, the body mass index (BMI), age, sex, diastolic pressure and mean arterial pressure (MAP) at time of measurements. Additional information including diseases such as diabetes and vascular disorders will be recorded. Social demographics including alcohol and tobacco use will be recorded. This is important as alcohol and tobacco use could also contribute to cardiovascular diseases. The skin pigmentation of each subject will be recorded. Two different methods will be used for this measurement. Each patient will be graded on a six point scale as described by Young (Young, 1997). Additionally, each subject will have their skin measured using a reflectance colorimeter. The colorimeter, DermaSpectrometer II (cyberDerm, Broomall, PA) uses visible light to measure the amount of light reflected off the skin. By measuring the light reflectance, the skin pigmentation can be measure (Clarys, 2000). Muscle oxygenation will be measured using a continuous dual wavelength near infrared spectrometer. Using the different absorption characteristics of deoxyhemoglobin and oxyhemoglobin, the concentration of oxyhemoglobin in the muscle at an approximate depth of 2.5 cm is determined. The INVOS cerebral oximeter (Somanetics, Troy, MI) will be used for all measurements.

Detailed Description

Not available

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • Male or Female between the ages of 18 and 75 years old
  • Subjects that have no lower extremity injuries.
  • Subject who are classified as being either light or dark skin pigmentation.
  • Subjects willing to participate in the study.
Exclusion Criteria
  • Patients with previous injury to either lower extremity
  • Patients with previously diagnosed vascular disease or insufficiency
  • Patients with pulmonary insufficiency or severe pulmonary injury
  • Patients not willing to consent to participate

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
1Measure of muscle oxygenationWe will use The INVOS cerebral oximeter to determine oxygen content in the healthy muscle. In addition, we will use a the DermaSpectrometer to determine if there are differences in our readings according to skin color.
1Skin pigmentation determinationWe will use The INVOS cerebral oximeter to determine oxygen content in the healthy muscle. In addition, we will use a the DermaSpectrometer to determine if there are differences in our readings according to skin color.
Primary Outcome Measures
NameTimeMethod
Measure from The INVOS cerebral oximeter and DermaSpectrometer1 day
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Grady Healthcare System

🇺🇸

Atlanta, Georgia, United States

© Copyright 2025. All Rights Reserved by MedPath